Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Eric Bjerkholt Sells 1,053 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt sold 1,053 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $96.19, for a total transaction of $101,288.07. Following the transaction, the chief financial officer owned 43,741 shares in the company, valued at $4,207,446.79. The trade was a 2.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Eric Bjerkholt also recently made the following trade(s):

• On Thursday, January 22nd, Eric Bjerkholt sold 1,421 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total transaction of $132,621.93.

Mirum Pharmaceuticals Price Performance

NASDAQ MIRM opened at $99.27 on Wednesday. The company has a market cap of $5.10 billion, a price-to-earnings ratio of -115.43 and a beta of 0.48. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. The stock’s fifty day moving average price is $78.36 and its 200 day moving average price is $71.54. Mirum Pharmaceuticals, Inc. has a 1 year low of $36.88 and a 1 year high of $99.44.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.15. The company had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The firm’s revenue was up 47.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.30) EPS. As a group, equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Wellington Management Group LLP increased its stake in shares of Mirum Pharmaceuticals by 566.8% in the 3rd quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock valued at $57,965,000 after purchasing an additional 672,118 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in Mirum Pharmaceuticals by 709.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock valued at $44,889,000 after purchasing an additional 536,674 shares during the period. Voloridge Investment Management LLC increased its position in shares of Mirum Pharmaceuticals by 2,116.6% in the third quarter. Voloridge Investment Management LLC now owns 389,574 shares of the company’s stock valued at $28,560,000 after buying an additional 371,999 shares in the last quarter. Balyasny Asset Management L.P. acquired a new position in shares of Mirum Pharmaceuticals during the 3rd quarter worth approximately $23,250,000. Finally, William Blair Investment Management LLC acquired a new position in shares of Mirum Pharmaceuticals during the 3rd quarter worth approximately $22,965,000.

Wall Street Analyst Weigh In

MIRM has been the subject of several research reports. Robert W. Baird lifted their price objective on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. Leerink Partners set a $100.00 target price on shares of Mirum Pharmaceuticals in a research report on Wednesday, December 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Thursday, January 22nd. Stifel Nicolaus lifted their price objective on Mirum Pharmaceuticals from $92.00 to $98.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Finally, Citizens Jmp boosted their price objective on Mirum Pharmaceuticals from $95.00 to $140.00 and gave the company a “market outperform” rating in a report on Friday, December 19th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $104.92.

More Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Director Patrick J. Heron purchased 131,425 shares at $68.48 (≈$9.0M), increasing his stake by ~40%, a strong insider vote of confidence in the company and its valuation. Director Form 4
• Positive Sentiment: HC Wainwright upgraded MIRM to Buy, raised the price target from $102 to $130 and published an aggressive FY2030 EPS projection ($6.16), signaling bullish long‑term expectations from a coverage analyst and supporting higher share valuations. HC Wainwright Coverage
• Positive Sentiment: Mirum completed the acquisition of Bluejay Therapeutics, expanding its rare-disease pipeline and global footprint—an acquisition likely viewed as strategically accretive and supportive of future revenue growth. Acquisition Announcement
• Positive Sentiment: Coverage and market reaction have pushed MIRM to a new 52‑week high following the analyst upgrade, which can attract momentum/technical buyers. 52‑Week High Article
• Negative Sentiment: CEO Christopher Peetz sold 6,831 shares at ~$96.19 (~$657K), reducing his stake by ~3.9%. CEO Form 4
• Negative Sentiment: Other senior exec sales the same day: COO Peter Radovich (3,143 shares), CFO Eric Bjerkholt (1,053 shares) and SVP Jolanda Howe (842 shares) — these reduce insider holdings and may concern some investors about near‑term insider liquidity. COO Form 4 CFO Form 4 SVP Form 4

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.